BEST UNLIMITED TURBO SHORT CERTIFICATE - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:01 2024-07-17 pm EDT | ||
| 2.465 EUR | +12.30% |
|
| Current month | -4.64% | ||
| 1 month | -11.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 2.465 | +12.30% |
| 24-07-16 | 2.195 | +1.86% |
| 24-07-15 | 2.155 | -3.58% |
| 24-07-12 | 2.235 | -7.07% |
| 24-07-11 | 2.405 | +7.13% |
Real-time Euronext Paris
Last update July 17, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| 16R7S | |
| ISIN | DE000SY1MU14 |
| Date issued | 2024-06-12 |
| Strike | 1,182 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 2.75 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.035 € |
|---|---|
| Lowest since issue | 2.03 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.6
USD
Average target price
901.5
USD
Spread / Average Target
-0.45%
- Stock Market
- Certificates
- 16R7S Certificat
